Novo Nordisk became the biggest European company, as measured by market value, earlier this week, so investors are starting to catch on. "We see anti-obesity drugs as one of the biggest drug classes ...

And research published in August found that liraglutide, an anti-obesity medication, can help restore adaptive learning abilities in those with obesity. What researchers are finding is that brain ...

We recently compiled a list of the 12 Best Biotech Stocks To Invest In According To Hedge Funds. In this article, we are ...

The release of OpenAI‘s ChatGPT chatbot in November 2022 unleashed a frenzy of investor interest in artificial intelligence ...

As film festival season gathers pace, the 68th BFI London Film Festival (LFF) has announced its full 2024 programme, ...

Scientists have developed a gel-based version of semaglutide that could reduce how often people need to take it.

Iscalimab is a monoclonal antibody commercialized by Novartis, with a leading Phase II program in Lupus Nephritis.

Odronextamab is a monoclonal antibody commercialized by Zai Lab, with a leading Phase III program in Marginal Zone B-cell Lymphoma.

Kepler Capital analyst David Evans maintained a Hold rating on Novo Nordisk (0QIU – Research Report) on September 6 and set a price ...